In this study, we elucidated a previously unrecognized role for circRNA-SFMBT2 in regulating tumor progression and drug resistance (Fig. 7T), revealing a potential therapeutic target to improve efficacy and overcome resistance in tamoxifen-based treatment of breast cancer. The gene discussed is SFMBT2; the disease is breast cancer.